02269.HK
WuXi Biologics (Cayman) Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 50.35
+0.50%Margins
Gross margin
47.5%
EBITDA margin
37.4%
EBIT margin
32.4%
Net margin
21.2%
FCF margin
11.8%
10.4%
Return on equity
7.7%
Return on assets
15.1%
Return on invested capital
0.37x
Asset turnover
HKD 5.4B
Cash from operations
HKD 3.78
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026